ReviewFrontiers in oncology2025
Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Numerous clinical and epidemiological studies have demonstrated that early screening can significantly reduce both the incidence and mortality of CRC. This review systematically summarizes recent advances in CRC screening technologies. It first reviews the current applications of traditional screening tools such as colonoscopy and fecal occult blood tests, then focuses on emerging molecular detection techniques based on DNA, RNA, proteins, and metabolites, as well as representative multi-omics integration approaches. Furthermore, it discusses the innovative use of artificial intelligence (AI) and image recognition technologies in CRC screening. At the guideline level, we compare recent updates and implementation differences among major national screening guidelines, including those of the U.S. Preventive Services Task Force (USPSTF), and analyze key challenges in current screening practices. Finally, we propose directions for future development. By integrating existing evidence, this review aims to provide clinical reference for transforming CRC screening from population-based to precision-based individualized prevention, promoting its wide, efficient, and sustainable implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.